Back

Does first line AF ablation improve outcome in hypertrophic cardiomyopathy patients?

26 August 2022 (09:06 - 09:24)
Organised by:
Congress Presentation Part of: When to consider AF ablation: outcome and survival in specific cohorts Treatment ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Antonio Creta

Barts Heart Centre, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Does first line atrial fibrillation ablation improve survival in HFrEF?
Professor J. Piccini (Durham, US)
Slides Video
Presentation thumbnail
Does first line atrial fibrillation ablation improve survival in HFpEF?
Professor G. Hindricks (Berlin, DE)
Slides Video
Presentation thumbnail
Does first line AF ablation improve outcome in asymptomatic patients?
Professor K. Chun (Frankfurt, DE)
Slides Video
Presentation thumbnail
When to consider AF ablation: outcome and survival in specific cohorts – discussion.
Video

Access the full session

Session thumbnail
When to consider AF ablation: outcome and survival in specific cohorts
Video

The Event

Event poster

ESC Congress 2022

26 August 2022 09:06 CET
You may be interested in
thumbnail
Congress Presentation
Follow-up outcomes of atrial fibrillation ablation in patients with hypertrophic cardiomyopathy: a single-center analysis
thumbnail
Congress Session
Treatment strategies for atrial fibrillation in heart failure
thumbnail
Congress Presentation
Left atrial strain and peak left ventricular outflow gradient are the main predictors of atrial fibrillation in patients with hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources